Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Gushika ico gihe, kurongorwa canke kwitwa umuvyeyi vyari nk'indoto za kure kuri Kinjal, kubera yari afise ikibazo gikomeye ca ...

Doctors harvest stem cells from the patient’s bone marrow and then send them off to a lab, where CRISPR is used to turn up the production of another, functional version of haemoglobin. This version is ...

Bluebird bio went public in 2013, raising approximately $116m through its IPO. The company has developed three US Food and Drug Administration (FDA)-approved gene therapy products, including Zynteglo ...

Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle and SK Capital Partners at a discount, ending ...

Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and ...

Morgan Stanley adds that the launch of Casgevy, the first gene-editing therapy ever approved, has been slow for sickle cell disease and transfusion-dependent beta thalassemia. Published first on ...